# A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

> **NCT06952803** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 700 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Saruparib
- **DRUG:** Placebo
- **DRUG:** Abiraterone + Prednisolone/Prednisone
- **DRUG:** Androgen Deprivation Therapy (ADT)

## Key facts

- **NCT ID:** NCT06952803
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2033-03-31
- **Final completion:** 2036-04-30
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06952803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06952803, "A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06952803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*